{"gene":"DPM3","run_date":"2026-06-09T23:54:42","timeline":{"discoveries":[{"year":2000,"finding":"Human DPM synthase is a trimeric complex consisting of three subunits: DPM1 (catalytic), DPM2 (regulatory), and DPM3. DPM3 (92 amino acids) associates with DPM1 via its C-terminal domain and with DPM2 via its N-terminal portion. DPM3 directly stabilizes DPM1, while DPM2 stabilizes DPM3. Overexpression of DPM3 in DPM2-null Lec15 cells restored DPM biosynthesis with increased DPM1 levels, demonstrating DPM3 directly stabilizes DPM1 independently of DPM2. DPM2 also plays a role in the enzymatic reaction, as activity was 10-fold higher in its presence.","method":"Complementation of DPM2-null Lec15 cells, co-purification, subunit overexpression, functional DPM biosynthesis assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — reconstitution via cell complementation, co-purification of subunits, enzymatic activity assay, multiple orthogonal methods in single study with functional validation","pmids":["10835346"],"is_preprint":false},{"year":2005,"finding":"DPM3 is an essential component of DPM synthase: CHO2.38 cells deficient in DPM3 show no detectable DPM synthase activity and lack GPI-anchored proteins. The coiled-coil domain near the C-terminus of DPM3 is critical for tethering DPM1 to the ER membrane and for enzyme activity. In the absence of DPM3, DPM1 is rapidly degraded by the proteasome; free DPM1 associates strongly with CHIP (C-terminus of Hsc70-interacting protein), a chaperone-dependent E3 ubiquitin ligase, indicating DPM1 is ubiquitinated at least in part by CHIP. The two N-terminal transmembrane regions of DPM3 showed no specific functions.","method":"DPM3-deficient CHO2.38 mutant cell line generation, DPM synthase activity assay, GPI-anchor surface staining, domain deletion/mutagenesis, co-immunoprecipitation with CHIP, proteasome inhibitor experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — loss-of-function cell line with defined phenotype, domain mutagenesis, enzymatic assay, protein interaction (CHIP co-IP), multiple orthogonal methods","pmids":["16280320"],"is_preprint":false},{"year":2009,"finding":"A pathogenic p.L85S missense mutation in the coiled-coil domain of DPM3 reduces its binding capacity for catalytic DPM1, leading to reduced DPM synthase activity. This reduces Dol-P-Man availability for all four Dol-P-Man-dependent glycosylation pathways in the ER, with the most prominent effect being strongly reduced O-mannosylation of alpha-dystroglycan in muscle, explaining the muscular dystrophy phenotype. Complementation of DPM3-deficient CHO2.38 cells confirmed pathogenicity.","method":"Sanger sequencing, CHO2.38 cell complementation, cotransfection binding assay (DPM3 L85S vs DPM1), DPM synthase activity assay, muscle biopsy O-mannosylation analysis by immunohistochemistry","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell complementation, direct binding assay with mutant vs wild-type, enzymatic activity measurement, tissue-level functional validation; multiple orthogonal methods","pmids":["19576565"],"is_preprint":false},{"year":2013,"finding":"A p.Gly152Val mutation in DPM1 reduces its binding to DPM3 (an essential non-catalytic subunit of the DPM complex), demonstrated by reduced co-immunoprecipitation of mutant DPM1 with DPM3 in transfected cells. DPM1 activity in patient fibroblasts was reduced by 80% without reduced substrate affinity, suggesting a decrease in amount of active enzyme rather than catalytic impairment.","method":"Fibroblast DPM1 enzymatic activity assay with substrate affinity measurement, transfection with tagged wild-type and mutant DPM1 followed by co-immunoprecipitation with DPM3","journal":"Molecular genetics and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP in transfected cells showing reduced DPM1-DPM3 binding for mutant, enzymatic assay in patient cells; single lab, two orthogonal methods","pmids":["23856421"],"is_preprint":false},{"year":2019,"finding":"In DPM3-CDG patients presenting with muscle dystrophy, both O-mannosylation of alpha-dystroglycan (αDG) and N-glycosylation of beta-dystroglycan (βDG) in skeletal muscle are affected — specifically, a consistent lack of one N-glycan on βDG was detected by western blot. This indicates that defects in DPM3 impair both O-glycosylation of αDG and N-glycosylation of βDG in skeletal muscle, suggesting these are tissue-specific readouts of DPM synthesis pathway deficiency.","method":"Skeletal muscle biopsy analysis, western blot of βDG N-glycosylation, immunostaining of αDG O-mannosylation in three DPM3-CDG patients","journal":"Journal of inherited metabolic disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct biochemical analysis of patient muscle tissue with two orthogonal glycosylation readouts; single lab, no functional rescue experiment","pmids":["30931530"],"is_preprint":false},{"year":2017,"finding":"A homozygous c.131T>G (p.Leu44Pro) substitution in DPM3 leads to a 50% reduction in DPM synthase enzymatic activity, and decreased availability of Dol-P-Man as the essential mannose donor substrate for POMT1/2 explains defective skeletal muscle alpha-dystroglycan O-glycosylation, causing limb girdle muscular dystrophy.","method":"Exome sequencing, DPM synthase activity measurement in patient cells, muscle biopsy alpha-dystroglycan glycosylation analysis","journal":"Neuromuscular disorders : NMD","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — enzymatic activity assay in patient cells plus tissue glycosylation analysis; single lab, two orthogonal methods","pmids":["28803818"],"is_preprint":false},{"year":2016,"finding":"Antisense morpholino-mediated depletion of dpm3 in zebrafish results in muscle disorganization, low DPM synthase complex activity, increased apoptotic nuclei, and hypoglycosylation of alpha-dystroglycan in muscle fibers, establishing a direct role for DPM3 in stabilizing muscle structure and DPM complex function in vivo.","method":"Antisense morpholino knockdown in zebrafish, DPM synthase activity assay, immunostaining for alpha-dystroglycan glycosylation, apoptosis detection in muscle","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo loss-of-function with defined enzymatic and glycosylation phenotype; single study, multiple readouts","pmids":["27291147"],"is_preprint":false},{"year":2001,"finding":"DPM3/prostin-1 expression is regulated by phospholipase C-gamma (PLCγ) signaling — pharmacological inhibition of PLCγ with U73122 induces prostin-1/DPM3 expression in PLCγ-competent prostate cancer cells. Exogenous overexpression of DPM3 in COS cells leads to apoptosis.","method":"Microarray expression analysis, pharmacological PLCγ inhibition (U73122), exogenous DPM3 overexpression in COS cells with apoptosis readout","journal":"Oncogene","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, pharmacological inhibitor (not specific), overexpression apoptosis assay without mechanistic follow-up","pmids":["11420690"],"is_preprint":false}],"current_model":"DPM3 is an essential non-catalytic subunit of the trimeric human Dol-P-Man (DPM) synthase complex that functions primarily through its C-terminal coiled-coil domain to tether the catalytic subunit DPM1 to the ER membrane and stabilize it from proteasomal degradation (mediated by the E3 ubiquitin ligase CHIP); DPM2 in turn stabilizes DPM3, creating a hierarchical stabilization cascade (DPM2→DPM3→DPM1), and loss of DPM3 abolishes DPM synthase activity, thereby reducing the mannosyl donor Dol-P-Man available for all four Dol-P-Man-dependent ER glycosylation pathways, with particularly severe consequences for O-mannosylation of alpha-dystroglycan and N-glycosylation of beta-dystroglycan in skeletal muscle."},"narrative":{"mechanistic_narrative":"DPM3 is an essential non-catalytic subunit of the trimeric ER-localized Dol-P-Man (DPM) synthase complex, where it physically bridges the regulatory subunit DPM2 and the catalytic subunit DPM1 to control production of the mannosyl donor Dol-P-Man [PMID:10835346]. Through a coiled-coil domain near its C-terminus, DPM3 tethers DPM1 to the ER membrane and stabilizes it; in the absence of DPM3, DPM1 is rapidly degraded by the proteasome after association with the chaperone-dependent E3 ubiquitin ligase CHIP, and DPM synthase activity together with downstream GPI-anchor biosynthesis is abolished [PMID:16280320]. DPM2 stabilizes DPM3 while DPM3 in turn stabilizes DPM1, establishing a hierarchical assembly in which DPM3 is the central structural linchpin [PMID:10835346]. Because DPM-derived Dol-P-Man feeds all four Dol-P-Man-dependent ER glycosylation pathways, loss or weakening of DPM3 disproportionately impairs O-mannosylation of alpha-dystroglycan in skeletal muscle, and N-glycosylation of beta-dystroglycan is also affected [PMID:19576565, PMID:30931530]. Hypomorphic missense mutations in the DPM3 coiled-coil domain (p.L85S, p.Leu44Pro) that reduce DPM1 binding or DPM synthase activity cause a congenital disorder of glycosylation presenting as muscular dystrophy [PMID:19576565, PMID:28803818]; depletion of dpm3 in zebrafish reproduces muscle disorganization and alpha-dystroglycan hypoglycosylation in vivo [PMID:27291147].","teleology":[{"year":2000,"claim":"Established that human DPM synthase is a trimeric complex and defined DPM3 as the bridging subunit that contacts DPM1 via its C-terminus and DPM2 via its N-terminus, resolving how the enzyme is assembled and stabilized.","evidence":"Complementation of DPM2-null Lec15 cells, co-purification of subunits, and functional DPM biosynthesis assay","pmids":["10835346"],"confidence":"High","gaps":["No structural model of the trimeric interface","Stoichiometry of the complex not directly determined","Did not address proteasomal turnover route of unassembled subunits"]},{"year":2005,"claim":"Demonstrated DPM3 is strictly required for enzyme activity and that its C-terminal coiled-coil tethers DPM1 to the ER membrane, while loss of DPM3 routes free DPM1 to CHIP-mediated proteasomal degradation, defining the molecular basis of DPM3-dependent DPM1 stabilization.","evidence":"DPM3-deficient CHO2.38 cell line, domain deletion/mutagenesis, DPM synthase and GPI-anchor assays, and co-immunoprecipitation with CHIP plus proteasome inhibition","pmids":["16280320"],"confidence":"High","gaps":["Direct ubiquitination of DPM1 by CHIP not reconstituted in vitro","Function of the two N-terminal transmembrane regions undefined","Whether other E3 ligases contribute not addressed"]},{"year":2009,"claim":"Connected DPM3 dysfunction to human disease by showing a coiled-coil domain missense mutation weakens DPM1 binding, lowers DPM synthase activity, and reduces alpha-dystroglycan O-mannosylation, explaining the muscular dystrophy phenotype.","evidence":"Sanger sequencing, CHO2.38 complementation, DPM3-DPM1 binding assay, enzyme activity assay, and muscle biopsy immunohistochemistry","pmids":["19576565"],"confidence":"High","gaps":["Why muscle/alpha-dystroglycan is preferentially affected over other pathways not mechanistically resolved","Quantitative threshold of residual activity for disease not defined"]},{"year":2013,"claim":"Showed the DPM3 interaction surface matters reciprocally from the DPM1 side, as a DPM1 mutation reducing DPM3 binding lowers active enzyme amount without impairing catalysis, reinforcing that complex assembly determines enzyme level.","evidence":"Patient fibroblast enzymatic activity with substrate affinity measurement and co-immunoprecipitation of tagged mutant DPM1 with DPM3","pmids":["23856421"],"confidence":"Medium","gaps":["Co-IP in transfected cells without reciprocal/structural validation","Direct effect on DPM3 stability not measured"]},{"year":2016,"claim":"Provided in vivo confirmation that DPM3 is required for muscle integrity, linking complex activity loss to alpha-dystroglycan hypoglycosylation and muscle apoptosis at the organismal level.","evidence":"Antisense morpholino knockdown of dpm3 in zebrafish with DPM synthase activity, alpha-dystroglycan immunostaining, and apoptosis assays","pmids":["27291147"],"confidence":"Medium","gaps":["Morpholino off-target effects not excluded by genetic rescue","Did not dissect which downstream glycosylation pathway drives the muscle phenotype"]},{"year":2017,"claim":"Identified an additional hypomorphic DPM3 allele causing ~50% activity loss and limb girdle muscular dystrophy, confirming partial loss of Dol-P-Man supply limits POMT1/2-dependent alpha-dystroglycan O-glycosylation.","evidence":"Exome sequencing, DPM synthase activity in patient cells, and muscle biopsy glycosylation analysis","pmids":["28803818"],"confidence":"Medium","gaps":["No complementation/rescue of the specific allele","Genotype-phenotype severity correlation across alleles not established"]},{"year":2019,"claim":"Refined the tissue-level glycosylation defect by showing DPM3-CDG impairs both O-mannosylation of alpha-dystroglycan and N-glycosylation of beta-dystroglycan in muscle, broadening the readout beyond alpha-dystroglycan alone.","evidence":"Skeletal muscle biopsy western blot of beta-dystroglycan N-glycan and alpha-dystroglycan immunostaining in three patients","pmids":["30931530"],"confidence":"Medium","gaps":["Single lab, no functional rescue","Mechanistic basis for selective loss of a single beta-dystroglycan N-glycan not determined"]},{"year":2001,"claim":"Reported a context outside glycosylation in which DPM3/prostin-1 expression is modulated by PLCgamma signaling and overexpression triggers apoptosis, raising an unresolved regulatory dimension.","evidence":"Microarray expression analysis, pharmacological PLCgamma inhibition (U73122), and DPM3 overexpression with apoptosis readout in COS cells","pmids":["11420690"],"confidence":"Low","gaps":["Non-specific inhibitor and overexpression-driven apoptosis without mechanistic follow-up","Link to DPM synthase function not established","Not independently confirmed"]},{"year":null,"claim":"How DPM3 selectively channels Dol-P-Man among the four downstream pathways and why muscle/dystroglycan glycosylation is preferentially sensitive remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No high-resolution structure of the assembled DPM complex","Mechanism of tissue-specific vulnerability undefined","Direct CHIP-mediated DPM1 ubiquitination not reconstituted"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[1]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[2,4,5]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,5]}],"complexes":["DPM synthase complex"],"partners":["DPM1","DPM2","STUB1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9P2X0","full_name":"Dolichol-phosphate mannosyltransferase subunit 3","aliases":["Dolichol-phosphate mannose synthase subunit 3","DPM synthase subunit 3","Dolichyl-phosphate beta-D-mannosyltransferase subunit 3","Mannose-P-dolichol synthase subunit 3","MPD synthase subunit 3","Prostin-1"],"length_aa":92,"mass_kda":10.1,"function":"Stabilizer subunit of the dolichol-phosphate mannose (DPM) synthase complex; tethers catalytic subunit DPM1 to the endoplasmic reticulum","subcellular_location":"Endoplasmic reticulum membrane","url":"https://www.uniprot.org/uniprotkb/Q9P2X0/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/DPM3","classification":"Not Classified","n_dependent_lines":272,"n_total_lines":1208,"dependency_fraction":0.2251655629139073},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/DPM3","total_profiled":1310},"omim":[{"mim_id":"618992","title":"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 15; MDDGB15","url":"https://www.omim.org/entry/618992"},{"mim_id":"615042","title":"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iu; CDG1U","url":"https://www.omim.org/entry/615042"},{"mim_id":"613155","title":"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH IMPAIRED INTELLECTUAL DEVELOPMENT), TYPE B, 1; MDDGB1","url":"https://www.omim.org/entry/613155"},{"mim_id":"612937","title":"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 15; MDDGC15","url":"https://www.omim.org/entry/612937"},{"mim_id":"609308","title":"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 1; MDDGC1","url":"https://www.omim.org/entry/609308"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/DPM3"},"hgnc":{"alias_symbol":["MGC34275","MGC125904","MGC125905"],"prev_symbol":[]},"alphafold":{"accession":"Q9P2X0","domains":[{"cath_id":"-","chopping":"32-92","consensus_level":"medium","plddt":88.6003,"start":32,"end":92},{"cath_id":"1.20.5","chopping":"2-31","consensus_level":"medium","plddt":85.1623,"start":2,"end":31}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9P2X0","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9P2X0-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9P2X0-F1-predicted_aligned_error_v6.png","plddt_mean":88.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=DPM3","jax_strain_url":"https://www.jax.org/strain/search?query=DPM3"},"sequence":{"accession":"Q9P2X0","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9P2X0.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9P2X0/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9P2X0"}},"corpus_meta":[{"pmid":"19576565","id":"PMC_19576565","title":"Deficiency of Dol-P-Man synthase subunit DPM3 bridges the congenital disorders of glycosylation with the dystroglycanopathies.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19576565","citation_count":153,"is_preprint":false},{"pmid":"19862844","id":"PMC_19862844","title":"Congenital disorders of glycosylation: an update on defects affecting the biosynthesis of dolichol-linked oligosaccharides.","date":"2009","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/19862844","citation_count":135,"is_preprint":false},{"pmid":"10835346","id":"PMC_10835346","title":"Human dolichol-phosphate-mannose synthase consists of three subunits, DPM1, DPM2 and DPM3.","date":"2000","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10835346","citation_count":117,"is_preprint":false},{"pmid":"23109149","id":"PMC_23109149","title":"DPM2-CDG: a muscular dystrophy-dystroglycanopathy syndrome with severe epilepsy.","date":"2012","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23109149","citation_count":112,"is_preprint":false},{"pmid":"23856421","id":"PMC_23856421","title":"Congenital disorder of glycosylation due to DPM1 mutations presenting with dystroglycanopathy-type congenital muscular dystrophy.","date":"2013","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23856421","citation_count":62,"is_preprint":false},{"pmid":"16280320","id":"PMC_16280320","title":"DPM1, the catalytic subunit of dolichol-phosphate mannose synthase, is tethered to and stabilized on the endoplasmic reticulum membrane by DPM3.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16280320","citation_count":44,"is_preprint":false},{"pmid":"15669674","id":"PMC_15669674","title":"Congenital disorder of glycosylation (CDG) type Ie. A new patient.","date":"2004","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/15669674","citation_count":40,"is_preprint":false},{"pmid":"30060766","id":"PMC_30060766","title":"Detection of variants in dystroglycanopathy-associated genes through the application of targeted whole-exome sequencing analysis to a large cohort of patients with unexplained limb-girdle muscle weakness.","date":"2018","source":"Skeletal muscle","url":"https://pubmed.ncbi.nlm.nih.gov/30060766","citation_count":40,"is_preprint":false},{"pmid":"12427759","id":"PMC_12427759","title":"In vivo interaction between the polyprenol phosphate mannose synthase Ppm1 and the integral membrane protein Ppm2 from Mycobacterium smegmatis revealed by a bacterial two-hybrid system.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12427759","citation_count":36,"is_preprint":false},{"pmid":"33200426","id":"PMC_33200426","title":"Genetic variations and clinical spectrum of dystroglycanopathy in a large cohort of Chinese patients.","date":"2021","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33200426","citation_count":31,"is_preprint":false},{"pmid":"28198708","id":"PMC_28198708","title":"Dystroglycanopathies: About Numerous Genes Involved in Glycosylation of One Single Glycoprotein.","date":"2015","source":"Journal of neuromuscular diseases","url":"https://pubmed.ncbi.nlm.nih.gov/28198708","citation_count":26,"is_preprint":false},{"pmid":"11420690","id":"PMC_11420690","title":"Dolichol-phosphate-mannose-3 (DPM3)/prostin-1 is a novel phospholipase C-gamma regulated gene negatively associated with prostate tumor invasion.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11420690","citation_count":24,"is_preprint":false},{"pmid":"16641202","id":"PMC_16641202","title":"A new intronic mutation in the DPM1 gene is associated with a milder form of CDG Ie in two French siblings.","date":"2006","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/16641202","citation_count":24,"is_preprint":false},{"pmid":"37239976","id":"PMC_37239976","title":"Metabolic Cardiomyopathies and Cardiac Defects in Inherited Disorders of Carbohydrate Metabolism: A Systematic Review.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37239976","citation_count":21,"is_preprint":false},{"pmid":"35279850","id":"PMC_35279850","title":"Synergistic use of glycomics and single-molecule molecular inversion probes for identification of congenital disorders of glycosylation type-1.","date":"2022","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/35279850","citation_count":19,"is_preprint":false},{"pmid":"22554691","id":"PMC_22554691","title":"Novel POMGNT1 point mutations and intragenic rearrangements associated with muscle-eye-brain disease.","date":"2012","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/22554691","citation_count":18,"is_preprint":false},{"pmid":"27291147","id":"PMC_27291147","title":"Dolichol-phosphate mannose synthase depletion in zebrafish leads to dystrophic muscle with hypoglycosylated α-dystroglycan.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27291147","citation_count":17,"is_preprint":false},{"pmid":"26299246","id":"PMC_26299246","title":"Dolichol phosphate mannose synthase from the pathogenic yeast Candida albicans is a multimeric enzyme.","date":"2015","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/26299246","citation_count":16,"is_preprint":false},{"pmid":"37662857","id":"PMC_37662857","title":"Fecal microbiota transplantation alleviates experimental colitis through the Toll-like receptor 4 signaling pathway.","date":"2023","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/37662857","citation_count":16,"is_preprint":false},{"pmid":"31741824","id":"PMC_31741824","title":"A mutation in mannose-phosphate-dolichol utilization defect 1 reveals clinical symptoms of congenital disorders of glycosylation type I and dystroglycanopathy.","date":"2019","source":"JIMD reports","url":"https://pubmed.ncbi.nlm.nih.gov/31741824","citation_count":14,"is_preprint":false},{"pmid":"6208373","id":"PMC_6208373","title":"Response of pulmonary cellular defenses to the inhalation of high concentrations of diesel exhaust.","date":"1984","source":"Journal of toxicology and environmental health","url":"https://pubmed.ncbi.nlm.nih.gov/6208373","citation_count":14,"is_preprint":false},{"pmid":"21727005","id":"PMC_21727005","title":"Intragenic rearrangements in LARGE and POMGNT1 genes in severe dystroglycanopathies.","date":"2011","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/21727005","citation_count":12,"is_preprint":false},{"pmid":"31266720","id":"PMC_31266720","title":"Dilated cardiomyopathy and limb-girdle muscular dystrophy-dystroglycanopathy due to novel pathogenic variants in the DPM3 gene.","date":"2019","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/31266720","citation_count":11,"is_preprint":false},{"pmid":"28803818","id":"PMC_28803818","title":"A homozygous DPM3 mutation in a patient with alpha-dystroglycan-related limb girdle muscular dystrophy.","date":"2017","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/28803818","citation_count":11,"is_preprint":false},{"pmid":"30931530","id":"PMC_30931530","title":"Toward understanding tissue-specific symptoms in dolichol-phosphate-mannose synthesis disorders; insight from DPM3-CDG.","date":"2019","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/30931530","citation_count":8,"is_preprint":false},{"pmid":"28357185","id":"PMC_28357185","title":"Microdeletion of chromosome 1q21.3 in fraternal twins is associated with mental retardation, microcephaly, and epilepsy.","date":"2017","source":"Intractable & rare diseases research","url":"https://pubmed.ncbi.nlm.nih.gov/28357185","citation_count":8,"is_preprint":false},{"pmid":"35932216","id":"PMC_35932216","title":"A recurrent homozygous missense DPM3 variant leads to muscle and brain disease.","date":"2022","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35932216","citation_count":7,"is_preprint":false},{"pmid":"1900279","id":"PMC_1900279","title":"Acquisition of thymidylate by the obligate intracytoplasmic bacterium Rickettsia prowazekii.","date":"1991","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/1900279","citation_count":7,"is_preprint":false},{"pmid":"14680801","id":"PMC_14680801","title":"A single point mutation resulting in an adversely reduced expression of DPM2 in the Lec15.1 cells.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/14680801","citation_count":7,"is_preprint":false},{"pmid":"21521073","id":"PMC_21521073","title":"Cloning and functional analysis of the dpm2 and dpm3 genes from Trichoderma reesei expressed in a Saccharomyces cerevisiae dpm1Δ mutant strain.","date":"2011","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21521073","citation_count":5,"is_preprint":false},{"pmid":"33255655","id":"PMC_33255655","title":"Yil102c-A is a Functional Homologue of the DPMII Subunit of Dolichyl Phosphate Mannose Synthase in Saccharomyces cerevisiae.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33255655","citation_count":4,"is_preprint":false},{"pmid":"30841283","id":"PMC_30841283","title":"First Report on Pathogenic Variability of Different Isolates of Diaporthe phaseolorum var. meridionalis on Soybean in Argentina.","date":"1999","source":"Plant disease","url":"https://pubmed.ncbi.nlm.nih.gov/30841283","citation_count":2,"is_preprint":false},{"pmid":"14680839","id":"PMC_14680839","title":"The divergent 5' ends of DPM2 mRNAs originate from the alternative splicing of two adjacent introns: characterization of the hamster DPM2 gene.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/14680839","citation_count":2,"is_preprint":false},{"pmid":"41154064","id":"PMC_41154064","title":"Selenium Supplementation Mitigates Copper-Induced Systemic Toxicity via Transcriptomic Reprogramming and Redox Homeostasis in Mice.","date":"2025","source":"Foods (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/41154064","citation_count":1,"is_preprint":false},{"pmid":"41437099","id":"PMC_41437099","title":"Clinical and genetic characterization of congenital disorders of glycosylation in 20 Chinese patients.","date":"2025","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/41437099","citation_count":0,"is_preprint":false},{"pmid":"41928102","id":"PMC_41928102","title":"Single-cell RNA and DNA methylome profiling reveal liquid helium vitrification enhances porcine parthenogenetically activated blastocyst viability.","date":"2026","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/41928102","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":21358,"output_tokens":2630,"usd":0.051762,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9809,"output_tokens":3200,"usd":0.064522,"stage2_stop_reason":"end_turn"},"total_usd":0.116284,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"Human DPM synthase is a trimeric complex consisting of three subunits: DPM1 (catalytic), DPM2 (regulatory), and DPM3. DPM3 (92 amino acids) associates with DPM1 via its C-terminal domain and with DPM2 via its N-terminal portion. DPM3 directly stabilizes DPM1, while DPM2 stabilizes DPM3. Overexpression of DPM3 in DPM2-null Lec15 cells restored DPM biosynthesis with increased DPM1 levels, demonstrating DPM3 directly stabilizes DPM1 independently of DPM2. DPM2 also plays a role in the enzymatic reaction, as activity was 10-fold higher in its presence.\",\n      \"method\": \"Complementation of DPM2-null Lec15 cells, co-purification, subunit overexpression, functional DPM biosynthesis assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — reconstitution via cell complementation, co-purification of subunits, enzymatic activity assay, multiple orthogonal methods in single study with functional validation\",\n      \"pmids\": [\"10835346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"DPM3 is an essential component of DPM synthase: CHO2.38 cells deficient in DPM3 show no detectable DPM synthase activity and lack GPI-anchored proteins. The coiled-coil domain near the C-terminus of DPM3 is critical for tethering DPM1 to the ER membrane and for enzyme activity. In the absence of DPM3, DPM1 is rapidly degraded by the proteasome; free DPM1 associates strongly with CHIP (C-terminus of Hsc70-interacting protein), a chaperone-dependent E3 ubiquitin ligase, indicating DPM1 is ubiquitinated at least in part by CHIP. The two N-terminal transmembrane regions of DPM3 showed no specific functions.\",\n      \"method\": \"DPM3-deficient CHO2.38 mutant cell line generation, DPM synthase activity assay, GPI-anchor surface staining, domain deletion/mutagenesis, co-immunoprecipitation with CHIP, proteasome inhibitor experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — loss-of-function cell line with defined phenotype, domain mutagenesis, enzymatic assay, protein interaction (CHIP co-IP), multiple orthogonal methods\",\n      \"pmids\": [\"16280320\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"A pathogenic p.L85S missense mutation in the coiled-coil domain of DPM3 reduces its binding capacity for catalytic DPM1, leading to reduced DPM synthase activity. This reduces Dol-P-Man availability for all four Dol-P-Man-dependent glycosylation pathways in the ER, with the most prominent effect being strongly reduced O-mannosylation of alpha-dystroglycan in muscle, explaining the muscular dystrophy phenotype. Complementation of DPM3-deficient CHO2.38 cells confirmed pathogenicity.\",\n      \"method\": \"Sanger sequencing, CHO2.38 cell complementation, cotransfection binding assay (DPM3 L85S vs DPM1), DPM synthase activity assay, muscle biopsy O-mannosylation analysis by immunohistochemistry\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell complementation, direct binding assay with mutant vs wild-type, enzymatic activity measurement, tissue-level functional validation; multiple orthogonal methods\",\n      \"pmids\": [\"19576565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"A p.Gly152Val mutation in DPM1 reduces its binding to DPM3 (an essential non-catalytic subunit of the DPM complex), demonstrated by reduced co-immunoprecipitation of mutant DPM1 with DPM3 in transfected cells. DPM1 activity in patient fibroblasts was reduced by 80% without reduced substrate affinity, suggesting a decrease in amount of active enzyme rather than catalytic impairment.\",\n      \"method\": \"Fibroblast DPM1 enzymatic activity assay with substrate affinity measurement, transfection with tagged wild-type and mutant DPM1 followed by co-immunoprecipitation with DPM3\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP in transfected cells showing reduced DPM1-DPM3 binding for mutant, enzymatic assay in patient cells; single lab, two orthogonal methods\",\n      \"pmids\": [\"23856421\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In DPM3-CDG patients presenting with muscle dystrophy, both O-mannosylation of alpha-dystroglycan (αDG) and N-glycosylation of beta-dystroglycan (βDG) in skeletal muscle are affected — specifically, a consistent lack of one N-glycan on βDG was detected by western blot. This indicates that defects in DPM3 impair both O-glycosylation of αDG and N-glycosylation of βDG in skeletal muscle, suggesting these are tissue-specific readouts of DPM synthesis pathway deficiency.\",\n      \"method\": \"Skeletal muscle biopsy analysis, western blot of βDG N-glycosylation, immunostaining of αDG O-mannosylation in three DPM3-CDG patients\",\n      \"journal\": \"Journal of inherited metabolic disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct biochemical analysis of patient muscle tissue with two orthogonal glycosylation readouts; single lab, no functional rescue experiment\",\n      \"pmids\": [\"30931530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A homozygous c.131T>G (p.Leu44Pro) substitution in DPM3 leads to a 50% reduction in DPM synthase enzymatic activity, and decreased availability of Dol-P-Man as the essential mannose donor substrate for POMT1/2 explains defective skeletal muscle alpha-dystroglycan O-glycosylation, causing limb girdle muscular dystrophy.\",\n      \"method\": \"Exome sequencing, DPM synthase activity measurement in patient cells, muscle biopsy alpha-dystroglycan glycosylation analysis\",\n      \"journal\": \"Neuromuscular disorders : NMD\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — enzymatic activity assay in patient cells plus tissue glycosylation analysis; single lab, two orthogonal methods\",\n      \"pmids\": [\"28803818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Antisense morpholino-mediated depletion of dpm3 in zebrafish results in muscle disorganization, low DPM synthase complex activity, increased apoptotic nuclei, and hypoglycosylation of alpha-dystroglycan in muscle fibers, establishing a direct role for DPM3 in stabilizing muscle structure and DPM complex function in vivo.\",\n      \"method\": \"Antisense morpholino knockdown in zebrafish, DPM synthase activity assay, immunostaining for alpha-dystroglycan glycosylation, apoptosis detection in muscle\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo loss-of-function with defined enzymatic and glycosylation phenotype; single study, multiple readouts\",\n      \"pmids\": [\"27291147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"DPM3/prostin-1 expression is regulated by phospholipase C-gamma (PLCγ) signaling — pharmacological inhibition of PLCγ with U73122 induces prostin-1/DPM3 expression in PLCγ-competent prostate cancer cells. Exogenous overexpression of DPM3 in COS cells leads to apoptosis.\",\n      \"method\": \"Microarray expression analysis, pharmacological PLCγ inhibition (U73122), exogenous DPM3 overexpression in COS cells with apoptosis readout\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, pharmacological inhibitor (not specific), overexpression apoptosis assay without mechanistic follow-up\",\n      \"pmids\": [\"11420690\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"DPM3 is an essential non-catalytic subunit of the trimeric human Dol-P-Man (DPM) synthase complex that functions primarily through its C-terminal coiled-coil domain to tether the catalytic subunit DPM1 to the ER membrane and stabilize it from proteasomal degradation (mediated by the E3 ubiquitin ligase CHIP); DPM2 in turn stabilizes DPM3, creating a hierarchical stabilization cascade (DPM2→DPM3→DPM1), and loss of DPM3 abolishes DPM synthase activity, thereby reducing the mannosyl donor Dol-P-Man available for all four Dol-P-Man-dependent ER glycosylation pathways, with particularly severe consequences for O-mannosylation of alpha-dystroglycan and N-glycosylation of beta-dystroglycan in skeletal muscle.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"DPM3 is an essential non-catalytic subunit of the trimeric ER-localized Dol-P-Man (DPM) synthase complex, where it physically bridges the regulatory subunit DPM2 and the catalytic subunit DPM1 to control production of the mannosyl donor Dol-P-Man [#0]. Through a coiled-coil domain near its C-terminus, DPM3 tethers DPM1 to the ER membrane and stabilizes it; in the absence of DPM3, DPM1 is rapidly degraded by the proteasome after association with the chaperone-dependent E3 ubiquitin ligase CHIP, and DPM synthase activity together with downstream GPI-anchor biosynthesis is abolished [#1]. DPM2 stabilizes DPM3 while DPM3 in turn stabilizes DPM1, establishing a hierarchical assembly in which DPM3 is the central structural linchpin [#0]. Because DPM-derived Dol-P-Man feeds all four Dol-P-Man-dependent ER glycosylation pathways, loss or weakening of DPM3 disproportionately impairs O-mannosylation of alpha-dystroglycan in skeletal muscle, and N-glycosylation of beta-dystroglycan is also affected [#2, #4]. Hypomorphic missense mutations in the DPM3 coiled-coil domain (p.L85S, p.Leu44Pro) that reduce DPM1 binding or DPM synthase activity cause a congenital disorder of glycosylation presenting as muscular dystrophy [#2, #5]; depletion of dpm3 in zebrafish reproduces muscle disorganization and alpha-dystroglycan hypoglycosylation in vivo [#6].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established that human DPM synthase is a trimeric complex and defined DPM3 as the bridging subunit that contacts DPM1 via its C-terminus and DPM2 via its N-terminus, resolving how the enzyme is assembled and stabilized.\",\n      \"evidence\": \"Complementation of DPM2-null Lec15 cells, co-purification of subunits, and functional DPM biosynthesis assay\",\n      \"pmids\": [\"10835346\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural model of the trimeric interface\", \"Stoichiometry of the complex not directly determined\", \"Did not address proteasomal turnover route of unassembled subunits\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrated DPM3 is strictly required for enzyme activity and that its C-terminal coiled-coil tethers DPM1 to the ER membrane, while loss of DPM3 routes free DPM1 to CHIP-mediated proteasomal degradation, defining the molecular basis of DPM3-dependent DPM1 stabilization.\",\n      \"evidence\": \"DPM3-deficient CHO2.38 cell line, domain deletion/mutagenesis, DPM synthase and GPI-anchor assays, and co-immunoprecipitation with CHIP plus proteasome inhibition\",\n      \"pmids\": [\"16280320\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ubiquitination of DPM1 by CHIP not reconstituted in vitro\", \"Function of the two N-terminal transmembrane regions undefined\", \"Whether other E3 ligases contribute not addressed\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Connected DPM3 dysfunction to human disease by showing a coiled-coil domain missense mutation weakens DPM1 binding, lowers DPM synthase activity, and reduces alpha-dystroglycan O-mannosylation, explaining the muscular dystrophy phenotype.\",\n      \"evidence\": \"Sanger sequencing, CHO2.38 complementation, DPM3-DPM1 binding assay, enzyme activity assay, and muscle biopsy immunohistochemistry\",\n      \"pmids\": [\"19576565\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why muscle/alpha-dystroglycan is preferentially affected over other pathways not mechanistically resolved\", \"Quantitative threshold of residual activity for disease not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed the DPM3 interaction surface matters reciprocally from the DPM1 side, as a DPM1 mutation reducing DPM3 binding lowers active enzyme amount without impairing catalysis, reinforcing that complex assembly determines enzyme level.\",\n      \"evidence\": \"Patient fibroblast enzymatic activity with substrate affinity measurement and co-immunoprecipitation of tagged mutant DPM1 with DPM3\",\n      \"pmids\": [\"23856421\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Co-IP in transfected cells without reciprocal/structural validation\", \"Direct effect on DPM3 stability not measured\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Provided in vivo confirmation that DPM3 is required for muscle integrity, linking complex activity loss to alpha-dystroglycan hypoglycosylation and muscle apoptosis at the organismal level.\",\n      \"evidence\": \"Antisense morpholino knockdown of dpm3 in zebrafish with DPM synthase activity, alpha-dystroglycan immunostaining, and apoptosis assays\",\n      \"pmids\": [\"27291147\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Morpholino off-target effects not excluded by genetic rescue\", \"Did not dissect which downstream glycosylation pathway drives the muscle phenotype\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified an additional hypomorphic DPM3 allele causing ~50% activity loss and limb girdle muscular dystrophy, confirming partial loss of Dol-P-Man supply limits POMT1/2-dependent alpha-dystroglycan O-glycosylation.\",\n      \"evidence\": \"Exome sequencing, DPM synthase activity in patient cells, and muscle biopsy glycosylation analysis\",\n      \"pmids\": [\"28803818\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No complementation/rescue of the specific allele\", \"Genotype-phenotype severity correlation across alleles not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Refined the tissue-level glycosylation defect by showing DPM3-CDG impairs both O-mannosylation of alpha-dystroglycan and N-glycosylation of beta-dystroglycan in muscle, broadening the readout beyond alpha-dystroglycan alone.\",\n      \"evidence\": \"Skeletal muscle biopsy western blot of beta-dystroglycan N-glycan and alpha-dystroglycan immunostaining in three patients\",\n      \"pmids\": [\"30931530\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, no functional rescue\", \"Mechanistic basis for selective loss of a single beta-dystroglycan N-glycan not determined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Reported a context outside glycosylation in which DPM3/prostin-1 expression is modulated by PLCgamma signaling and overexpression triggers apoptosis, raising an unresolved regulatory dimension.\",\n      \"evidence\": \"Microarray expression analysis, pharmacological PLCgamma inhibition (U73122), and DPM3 overexpression with apoptosis readout in COS cells\",\n      \"pmids\": [\"11420690\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Non-specific inhibitor and overexpression-driven apoptosis without mechanistic follow-up\", \"Link to DPM synthase function not established\", \"Not independently confirmed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How DPM3 selectively channels Dol-P-Man among the four downstream pathways and why muscle/dystroglycan glycosylation is preferentially sensitive remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure of the assembled DPM complex\", \"Mechanism of tissue-specific vulnerability undefined\", \"Direct CHIP-mediated DPM1 ubiquitination not reconstituted\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [2, 4, 5]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 5]}\n    ],\n    \"complexes\": [\"DPM synthase complex\"],\n    \"partners\": [\"DPM1\", \"DPM2\", \"STUB1\"],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}